This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Medicines must stayed aligned with EU after Brexit, UK health lawmakers warn

( March 21, 2018, 00:01 GMT | Official Statement) -- MLex Summary: The UK government must be aware of how "seriously adversely affected" the pharmaceuticals sector would be by a "no deal" Brexit outcome, according to Parliament's Health and Social Care Committee. It believes regulatory alignment with the European Medicines Agency is in the best interest for both sides and noted that the EU's insistence that the single market cannot be used on a sector-by-sector basis is a cause for concern.The statement follows. The full report is attached below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections